| Document |
Document Title |
|
WO/2013/034119 |
The invention relates to phenoxy derivatives having glycosidically bound sugar residues, to pharmaceutical compositions containing such compounds, to the uses of such compounds and compositions, and to methods for producing such compound...
|
|
WO/2013/034622 |
This invention relates to a new crystalline form of Pridopidine, a drug substance currently in development for the treatment of Huntington's disease. More specifically the invention provides polymorphic Form II of the Pridopidine hydroch...
|
|
WO/2013/035109 |
The present invention relates to a process for the preparation of Asenapine maleate with an avoiding column chromatography by use of DBN or DBA.
|
|
WO/2013/034506 |
The present invention relates to compounds of formula (I) wherein R1, R2, R3, R5, W, X, X1, Y, Y1, Z and Z1 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit...
|
|
WO/2013/034755 |
The present invention is directed to triazolopyrazine compounds of Formula (I). Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds as therapeutic agents treat...
|
|
WO/2013/036224 |
The invention concerns the use of competitive AMPA receptor antagonists for the treatment or prevention of photosensitive epilepsy.
|
|
WO/2013/035712 |
The purpose of the present invention is to provide a novel medicinal agent and a novel method both of which can be used for treating ALS (amyotrophic lateral sclerosis), preventing the progression of the phase of ALS, treating a symptom ...
|
|
WO/2013/035826 |
Provided are: a fused heterocyclic compound that has an excellent PDE10A inhibitory effect; and a use of the fused heterocyclic compound. A compound represented by formula (I) or a salt thereof. (In the formula, R1 represents an optional...
|
|
WO/2013/034173 |
A tablet composition for a controlled and pH-independent release of the pharmaceutically active compound pramipexole from the tablet matrix after oral administration has been provided. The composition comprises a water-soluble, preferabl...
|
|
WO/2013/036596 |
|
|
WO/2013/036875 |
The present invention relates to methods of producing chondrocytes, improving the phenotype of a chondrocyte population, promoting chondrogenesis, maintaining a cell population in a differentiated state or increasing the number of cells ...
|
|
WO/2013/035892 |
Provided is a superior, novel heterocyclic compound with improved solubility in oil such as sesame oil and benzyl benzoate, which has a broader treatment spectrum, causes less side effects, and is superior in tolerability and safety, and...
|
|
WO/2013/035833 |
A morphinan derivative represented by general formula (I) or an acid addition salt thereof is used as an analgesic. (In the formula, R1 represents a hydrogen atom, a C1-6 alkyl group, a cycloalkyl alkyl group (wherein the cycloalkyl moie...
|
|
WO/2013/036196 |
The present invention relates to novel labelled compounds of formula (I) (C)n-B-(A)m-B-(C)n (I) wherein m is 0 or 1, and n is independently 0, 1, 2 or 3, A, each B and each C are independently selected from phenylene and five- and six-me...
|
|
WO/2013/032011 |
[Problem] To provide a glycosylated polypeptide having an affinity to somatostatin receptors, and, compared to somatostatins, having improved in-blood stability. [Solution] The glycosylated polypeptide is characterized by at least one am...
|
|
WO/2013/031729 |
The purpose of the present invention is to provide a drug having excellent prophylactic or therapeutic effect against cardiovascular complications of diabetes, the drug containing a compound for inhibiting neutral fat accumulation in car...
|
|
WO/2013/032351 |
The invention provides a drug selected from eslicarbazepine acetate and eslicarbazepine, for use in treating or preventing a disorder selected from epilepsy, affective disorders, schizoaffective disorders, bipolar disorders, neuropathic ...
|
|
WO/2013/030218 |
The present invention relates to quinazolin-4-one compounds of formula (I'), their process of preparation and uses thereof. These compounds are useful as selective and reversible inhibitors of ubiquitin specific proteases, particularly U...
|
|
WO/2013/031935 |
Provided is a stable pharmaceutical composition containing ibuprofen and scopolamine butylbromide. A pharmaceutical composition comprising the following components (A), (B) and (C): (A) ibuprofen; (B) scopolamine butylbromide; and (C) at...
|
|
WO/2013/030177 |
The invention relates to a tablet formulation based on paracetamoland oxycodone. The invention also relates to a process for preparing said tablet and to the use thereof.
|
|
WO/2013/030692 |
The disclosures herein provide compounds of formula (I) or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositio...
|
|
WO/2013/030665 |
The present disclosure provides substituted pyrimidine compounds of Formula (I), and the pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein A1, X, A2, W1, W2, W3, E, Z, and R4 are defined as set forth in the speci...
|
|
WO/2013/033246 |
|
|
WO/2013/030722 |
The present invention provides crystalline lurasidone hydrochloride, processes for its preparation, a pharmaceutical composition comprising it and its use for the treatment of schizophrenia.
|
|
WO/2013/030374 |
A novel crystalline form of a compound is disclosed.
|
|
WO/2013/029338 |
Disclosed are novel retinoid-related orphan receptor gamma (RORy) modulators and their use in the treatment of diseases mediated by RORy.
|
|
WO/2013/033246 |
The present invention relates to novel benzodiazepinone compounds of Formulae (I) wherein R1, R2, R4, R6, R7, R8, R9, and R10 are as defined herein. The invention also relates to pharmaceutical compositions containing such compounds, met...
|
|
WO/2013/030713 |
Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I), as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, me...
|
|
WO/2013/030218 |
The present invention relates to quinazolin-4-one compounds of formula (I'), their process of preparation and uses thereof. These compounds are useful as selective and reversible inhibitors of ubiquitin specific proteases, particularly U...
|
|
WO/2013/032012 |
[Problem] To provide a glycosylated polypeptide having affinity to somatostatin receptors and, compared to somatostatins, having improved in-blood stability. [Solution] The glycosylated polypeptide is characterized by at least two amino ...
|
|
WO/2013/033037 |
Described herein are novel compositions and methods of treatment addressing diseases such as neurodegenerative diseases, including prion diseases and Alzheimer's disease.
|
|
WO/2013/029431 |
Disclosed are tosylate salts of benzodiazepine derivatives, their polymorphic forms, preparation methods and uses thereof, in particular to a tosylate salt of 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4H-imidazo[1,2-a][1
,4]benzodiazepine...
|
|
WO/2013/033602 |
The invention relates to fatty acid amides; compositions comprising an effective amount of a fatty acid amide; and methods for treating or preventing cancer, a metabolic disease or a neurodegenerative disease comprising the administratio...
|
|
WO/2013/029136 |
The present invention provides tianeptine derivatives, especially N-alkyl and N-alkenyl derivatives, use thereof, pharmaceutical compositions comprising same, and method for producing same. The tianeptine-derived compounds can potentiall...
|
|
WO/2013/031992 |
Provided is an adhesive patch which offers excellent rivastigmine storage stability and increase the skin permeability of rivastigmine to such an extent that the amount of percutaneous absorption needed to treat Alzheimer's disease is ob...
|
|
WO/2013/030409 |
The present invention refers to a pharmaceutical composition for use in the treatment of a neurodegenerative disease.
|
|
WO/2013/033662 |
A diffusion rate limiting matrix is utilized to lingually and/or sublingually deliver thioctic acid. This limited release matrix is intended for general nutritional supplementation and/or the treatment of various physiological disorders....
|
|
WO/2013/032804 |
A dual H1 inverse agonist/5-HT2A receptor antagonist of the formula (I), its uses, and methods for its preparation are described.
|
|
WO/2013/026806 |
The present invention relates to novel thiazolo[5,4-ƒ]quinazoline compounds and methods that are useful in the amelioration, treatment or control of Down's syndrome or early Alzheimer's disease or in the amelioration, treatment or contr...
|
|
WO/2013/026852 |
Mecamylamine is a general nicotinic acetylcholine receptor (nAChR) antagonist that was one of the first anti-hypertensive agents. Since its demise as an anti-hypertensive drug, mecamylamine has been shown to aid smoking cessation (in hum...
|
|
WO/2013/028587 |
The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and t...
|
|
WO/2013/027150 |
The disclosures herein provide compounds of formula 1 or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions...
|
|
WO/2013/027000 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them an...
|
|
WO/2013/026547 |
The present invention relates to the use of rotigotine for the effective treatment of a condition or disorder selected from neglect, stroke, conditions associated with stroke and/or following stroke. The invention also relates to a rotig...
|
|
WO/2013/026896 |
The invention relates to peptides comprising an amino acid sequence of or derived from a claudin protein for use as a pharmaceutical agent, in particular as an adjuvant or drug delivery-enhancing agent in pain therapy.
|
|
WO/2013/026455 |
The present invention provides compounds comprising a substructure of below formula 3: or a salt or prodrug thereof and the use of such compounds in treatment of e.g. CNS disorders.
|
|
WO/2013/028909 |
Provided herein are methods for treatment of sleep-related breathing disorders comprising administration of a dopamine-2 receptor antagonist and a sympathomimetic agent to an individual suffering from or suspected to be suffering from a ...
|
|
WO/2013/026852 |
Mecamylamine is a general nicotinic acetylcholine receptor (nAChR) antagonist that was one of the first anti-hypertensive agents. Since its demise as an anti-hypertensive drug, mecamylamine has been shown to aid smoking cessation (in hum...
|
|
WO/2013/027986 |
The present invention relates to a method of screening for modulator of chaperonin that is involved in protein aggregation inducing neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease, use...
|
|
WO/2013/027001 |
The present invention provides compounds of formula (1) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, m, n, p, q, Q1, Q2, Q3, Q4, Q5, Q6,...
|
